Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
Public ClinicalTrials.gov record NCT01210001. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Trial of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite a Background Therapy of Pioglitazone Alone or in Combination With Metformin
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will investigate the efficacy and safety of BI 10773 in type 2 diabetic patients in order to provide these data for approval for BI 10773 by regulatory authorities as an antidiabetic agent as add-on therapy to pioglitazone alone or in combination with metformin.
Study identification
- NCT ID
- NCT01210001
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 499 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2010 (Type not available)
- Primary completion
- Apr 2012 (Actual)
- Completion
- Not listed
- Last update posted
- Jun 17, 2014
Started 2010
United States locations
- U.S. sites
- 24
- U.S. states
- 14
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1245.19.10056 Boehringer Ingelheim Investigational Site | Muscle Shoals | Alabama | — | — |
| 1245.19.10162 Boehringer Ingelheim Investigational Site | Glendale | Arizona | — | — |
| 1245.19.10161 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 1245.19.10046 Boehringer Ingelheim Investigational Site | Tempe | Arizona | — | — |
| 1245.19.10070 Boehringer Ingelheim Investigational Site | Irvine | California | — | — |
| 1245.19.10047 Boehringer Ingelheim Investigational Site | La Mesa | California | — | — |
| 1245.19.10149 Boehringer Ingelheim Investigational Site | Rancho Cucamonga | California | — | — |
| 1245.19.10163 Boehringer Ingelheim Investigational Site | Riverside | California | — | — |
| 1245.19.10131 Boehringer Ingelheim Investigational Site | West Hills | California | — | — |
| 1245.19.10141 Boehringer Ingelheim Investigational Site | Milford | Connecticut | — | — |
| 1245.19.10133 Boehringer Ingelheim Investigational Site | Jupiter | Florida | — | — |
| 1245.19.10085 Boehringer Ingelheim Investigational Site | Plantation | Florida | — | — |
| 1245.19.10077 Boehringer Ingelheim Investigational Site | Perry | Georgia | — | — |
| 1245.19.10014 Boehringer Ingelheim Investigational Site | Dubuque | Iowa | — | — |
| 1245.19.10160 Boehringer Ingelheim Investigational Site | Essex | Maryland | — | — |
| 1245.19.10003 Boehringer Ingelheim Investigational Site | Dearborn | Michigan | — | — |
| 1245.19.10059 Boehringer Ingelheim Investigational Site | New Hyde Park | New York | — | — |
| 1245.19.10123 Boehringer Ingelheim Investigational Site | Smithtown | New York | — | — |
| 1245.19.10071 Boehringer Ingelheim Investigational Site | Asheboro | North Carolina | — | — |
| 1245.19.10086 Boehringer Ingelheim Investigational Site | Salisbury | North Carolina | — | — |
| 1245.19.10008 Boehringer Ingelheim Investigational Site | Marion | Ohio | — | — |
| 1245.19.10033 Boehringer Ingelheim Investigational Site | Chattanooga | Tennessee | — | — |
| 1245.19.10112 Boehringer Ingelheim Investigational Site | Memphis | Tennessee | — | — |
| 1245.19.10002 Boehringer Ingelheim Investigational Site | Norfolk | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01210001, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 17, 2014 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01210001 live on ClinicalTrials.gov.